CEACAM5 and breast cancer: The current cohort indicated that CEA and CA15-3 TMs combination did not achieve better diagnostic efficiency in BC patients, with AUC difference = 0.16 and a p-value of 0.13, which was not different from either TM alone in other previous studies (51–52).